Parisa Ghahremanifard, a Master of Science student at the University of Calgary is part of a research project hoping to improve the lives of patients with oral cancers, one of the most common cancers of the head and neck region. 

 

“My MSc is in  Biochemistry and Molecular Biology and I work at Dr. Pinaki Bose’s lab at the Arnie Charbonneau Cancer Institute where I’m currently researching ways to  stop oral cancer progression in patients.”

 

Parisa’s study focuses on cancer immunotherapy. Immunotherapy treatments harness the body’s immune system to attack tumours. A key step involves helping the body’s cancer-fighting T-cells recognize which cells are cancerous.

 

“Cancerous cells are as smart as we are because we literally share the same DNA. So as we try to find a way to treat patients with chemotherapy or radiation, the cancer cells find a way to fight back and resist the treatment. I think it’s amazing to destroy cancerous cells with the tool that God has given us all, our own immune cells!!”

 

With the new Calgary Cancer Centre being one of the largest comprehensive cancer centres in North America, it means bringing together researchers, medical teams, prevention experts, patients and families in ways never before possible. Which is an exciting prospect for researchers like Parisa.

 

“I can’t wait to continue my project in our new lab at the Calgary Cancer Centre. I think it’s a brilliant idea to gather all cancer professionals and patients in one place. I believe if we all work together and look at cancer from different perspectives hopefully with every small step we will finally OWN.CANCER. Even if all this work helps one person enjoy their life a few days more, I believe that it will all be worth it.”

____

 

At the new Calgary Cancer Centre, we’re bringing together researchers, medical teams, prevention experts, patients and families in ways never before possible.

Click here to learn about the five critical areas in which we aim to tackle cancer.

You can help clinicians and researchers like Parisa Ghahremanifard perform world-class cancer research by making a donation to the OWN.CANCER campaign today.

Click here to Donate.

 

 

Dr. Amanda Khan,  a second-year radiation oncology resident physician at the University of Calgary, was inspired to pursue medicine after witnessing the care her brother received when he was diagnosed with leukemia.“The ability to help patients through their cancer journey is a privilege and I am truly living my life’s dream by helping patients the way my brother’s oncologist helped him,” she says. 

In order to best serve patients, Dr. Khan decided to train as a clinician-scientist. This is a physician with a medical degree who also obtains a Ph.D. degree to perform clinically relevant research.

“Not only do I see patients in the clinic and help treat their cancer, but I also perform research that can directly impact their care and improve their quality of life.”

After receiving her MD/Ph.D. dual degree at the University of Toronto, she chose the University of Calgary for residency because of the world-class clinicians and the upcoming Calgary Cancer Centre which will be one of the largest comprehensive cancer centres in North America. 

“In terms of Calgary’s excellence, not only do the radiation oncologists here engage in incredible cancer research but their clinical knowledge and bedside manner made such an impression on me during my elective here, that I was willing to move halfway across the country during the pandemic to train with them. I also chose to train at the University of Calgary because of the new Calgary Cancer Centre. Being able to be at the vanguard of cancer care and treatment delivery in Canada is an incredible opportunity. My future goal is to become a clinician-scientist radiation oncologist at the Calgary Cancer Centre and have my own research laboratory to help make cancer treatments safer and better.”

To Dr. Khan, the words OWN.CANCER reflects exactly what she tries to do every day.

“As a radiation oncology resident physician, I try to take control over cancer and own it via imaging, safe radiation delivery and research so that my patients can live their lives.”

 

---

At the new Calgary Cancer Centre, we’re bringing together researchers, medical teams, prevention experts, patients and families in ways never before possible.

Click here to learn about the five critical areas in which we aim to tackle cancer.

You can help clinicians and researchers like Amanda perform world-class cancer research by making a donation to the OWN.CANCER campaign today.

Click here to Donate.

 

When Milan Heck first noticed a lump on her hip, she and her family blamed it on the boot cast she wore to heal her broken ankle. But on Aug. 31, 2015, they learned that an abnormal gait wasn’t the culprit. Heck had a tumour. Two-and-a-half weeks later, she found herself at the Alberta Children’s Hospital waiting to meet her oncology team. 

“That meeting is when everything became real,” says Heck, who’s now a second-year Bachelor of Health Sciences student at the Cumming School of Medicine (CSM). “That’s the first time I recall thinking, ‘That’s it. This is cancer.’ I felt numb. I put on a stoic face, surrounded myself with people and tried to make the situation as lighthearted as possible. I think that’s what has helped me cope throughout the years.”

Heck was diagnosed with alveolar soft part sarcoma (ASPS), a malignant soft tissue tumour which starts in the soft connective tissues of the body such as fat, muscles or nerves. ASPS usually starts in the legs or arms and most often metastasizes to the lungs but can involve other organs, such as the brain or bones.

“What felt like a small lump turned out to be a tumour the size of a grapefruit,” says Heck. “Upon initial diagnosis, my doctors also found a lesion on my brain and 13 lesions across my lungs. I was completely in shock.” 

Over the past six years, Heck has undergone nine surgeries, two radiation treatments and has tried numerous medications. Many of which caused unpleasant side effects and complications. While experts do their best to recommend therapies, they face many challenges when diagnosing and treating them.

But thanks to the participation of cancer patients and innovative research methods, new treatment options are on the horizon. 

 

Developing a better understanding

Dr. Jennifer Chan, MD, a pathologist and the scientific director of the CSM’s Arnie Charbonneau Cancer Institute, explains that there’s no standard treatment for most rare cancers because there’s less research on them and, in turn, not enough information to support drug development.

“The good news is that researchers are no longer studying ‘cancer,’ we’re investigating the various types and subtypes of cancer, and we’re doing it in creative and innovative ways,” says Chan who’s also an associate professor in the Department of Pathology & Laboratory Medicine. “The better we understand a cancer, the better we can treat it.”

One of these ways is by banking leftover clinical samples for research. Another is by using the collected tissue samples to make tumour models from the patients’ cancers. The models allow researchers to study the development and progression of a tumour, and test new treatments to see which ones are effective. 

Thousands of Calgarian patients are making this research possible by contributing pieces of tumour tissue extracted during surgical or biopsy procedures. Heck is one of them, and her samples are currently being used by a team of UCalgary researchers to better understand ASPS.     

 

Giving a gift for research

“When one of my surgeons talked to me about participating, it was an easy decision for me,” says Heck. “Knowing that my donation could help generate knowledge about ASPS, I immediately said ‘yes.’”

To date, Heck has donated three samples, which have been stored within the Charbonneau Institute’s Clark H. Smith Tumour Centre’s tissue bank — a biorepository that specializes in neurological and pediatric diseases and provides samples to local, national and international researchers. The biobank is directed by Dr. Chan who explains that collected samples can sometimes be stored for a while before they’re used. Earlier this year, Heck’s samples were pulled and a team of researchers is now focused on finding new treatments.

“Choosing to participate is like giving a gift for research,” says Chan. “Understanding tumour biology is a critically important step in the process of finding new therapeutic approaches, reducing toxicity of current therapies and improving patient experience. Without participant samples, we wouldn’t be able to model or study these tumours in the same way we are now.”

 

A more tailored approach

Dr. Douglas Mahoney, PhD, a member of the research team and an associate professor in the departments of Microbiology, Immunology & Infectious Diseases and Biochemistry & Molecular Biology, explains that the live samples from the biobank are what allow researchers to test treatments and develop more personalized treatment plans. 

“The more we learn from these studies, the more tailored our treatments will become,” says Mahoney. “Up until now, this rare disease didn’t have many preclinical models and we’ve generated them. Now we’re starting to use cell-based therapies to see if they’ll work in vivo.”

Mahoney and his team are using Chimeric Antigen Receptor or CAR T-cell immunotherapy, which uses synthetic biology to modify T-cells — a type of white blood cell that’s essential to the immune system —to recognize and kill the cancer cells. This therapy has successfully treated children and adult patients with forms of leukemia and lymphoma and there’s growing evidence that engineered immune cells also have the potential to be broadly applicable across more types of cancer.

The team has built a new CAR T-cell therapy specifically for ASPS and is testing it against Heck’s cancer. One day, it could become a treatment for ASPS patients like her. 

“My hope is for safer, better therapies for cancer patients,” says Mahoney. “There’s no guarantee that we ever achieve that, but we have the tools, ideas and right people to take a fantastic shot at it.” Heck agrees. 

“New ways of treating cancer are on the horizon,” she says. “Even if I don’t see that happen in my lifetime or receive any of the treatment, I know that there’s potential for someone else down the line to benefit from the knowledge that’s being created, and that’s a silver lining.” 

 

In 2023, the new Calgary Cancer Centre (CCC) will open and will be the largest comprehensive cancer care centre in Canada. The space will create a fully-integrated environment that enables experts like Drs. Chan and Mahoney to efficiently advance their research from discovery, invention, preclinical studies and clinical trials; improving the experience and prognosis of cancer patients. Learn how you can help make a difference by contributing to the CCC or tissue bank. 

 

Dr. Jennifer Chan, MD, is the scientific director of the Arnie Charbonneau Cancer Institute and an associate professor in the Department of Pathology & Laboratory Medicine at the Cumming School of Medicine. She is also a member of the Alberta Children’s Hospital Research Institute at the University of Calgary.  

Dr. Douglas Mahoney, PhD, is an assistant professor in the departments of Microbiology, Immunology and Infectious Diseases and Biochemistry & Molecular Biology at the Cumming School of Medicine. He is also a member of the Alberta Children’s Hospital Research Institute, Arnie Charbonneau Cancer Institute, and Snyder Institute for Chronic Diseases at the University of Calgary.

 

Written by Melanie Tibbetts for the Cumming School of Medicine. 

Dr. Jose Monzon explains how clinical trial research that begins at Calgary’s Tom Baker Cancer Centre has the potential to impact cancer patients around the globe.

The clinical trials that come to life at the Tom Baker Cancer Centre can change lives beyond Calgary, the province or even Canada. Dr. Jose Monzon knows this from experience.

“When you do clinical trials research, you’re making impacts not only on your community,” explains Monzon, “but also on patients worldwide.”

Monzon is a medical oncologist and medical leader for the Clinical Research Unit at the Tom Baker. He helps manage and oversee the roughly 150 clinical trials happening in the centre at any given time while also leading trials of his own. The role includes meeting with clinical trial unit leaders to discuss trial activities, brainstorm ways to improve the process for patients and find avenues to open other trials. Beyond research, Monzon sees patients and enrolls eligible candidates into existing trials.

While the job can be varied and complex, Monzon’s rationale behind why he does what he does is simple.

“To be able to help patients through that process and that journey seemed important to me,” he says. “I learned very early on that with research, you can make huge impacts on patient outcomes.”

Simply, a clinical trial is the testing of a novel agent — often a drug — or a previously known agent in a unique setting to evaluate its safety, responsiveness, toxicity and, of course, its effect on survival. Eligible patients are enrolled in trials and tracked through regular tests to gauge how the agent is working versus the previously established treatment option.

After three phases with different goals at each, the treatment can potentially become the new standard of care.

According to Monzon, the Tom Baker is unique in its opportunity for investigator-initiated trials, often supported by the Alberta Cancer Foundation. This reputation is attractive for academic researchers across the country and is part of what drew him to Calgary. Monzon has helped lead a handful of trials spawned from findings at the Tom Baker, such as an ongoing look into the positive effects of statins, which are cholesterol medications, on rectal cancer patients undergoing chemotherapy and radiation therapy.

The idea for the trial came from a patient database assembled by fellow oncologist Dr. Michael Vickers during his time working at the Tom Baker. The opportunity to work together and collaborate to create new trials in Calgary not only helps researchers, but also benefits patients.

“These are homegrown ideas. That’s the beauty of it,” says Monzon. “These are trials that can open up options for our patients here.”

Each year, the Tom Baker Cancer Centre enrolls around 400 patients into clinical trials, creating opportunities to pursue alternative treatments that can lead to life-saving results. With the Tom Baker acting either as the starting point or as a contributor to larger trials, the potential for widespread change is immense. And at its core, it all starts with the patients.

“[Clinical trials] provide these options of novel treatments, and it gives the patients hope of responding and prolonging life, but it also helps other cancer patients,” says Monzon. “We have everything to thank for the patients involved in clinical trials. Our goal is to have a clinical trial opportunity for every single patient who comes to the cancer centre and that patient and clinician trial activity should be celebrated and encouraged.”

Brief Glossary Of Clinical Trial Terms

 

Clinical trial: The testing and tracking of a new treatment to evaluate its effects on human health outcomes.

Industry-sponsored trial: When a business or corporation, like a pharmaceutical company, conceives, plans and funds a clinical trial. 

Investigators: The researchers leading and conducting work on a clinical trial. 

Investigator-initiated trial: When an independent researcher has an idea for a trial they want to conduct, conceive, plan and run themselves.

Phases Of Clinical Trials

Bench Research: Prior to clinical trials, bench researchers run tests outside of humans. This often means seeing how cells react within cancer cell line models or animal models and how novel agents may show activity in or inhibit pathways.

Phase 1: Often the “first-in-human” trial, phase one starts testing the safety and tolerability of a drug. Researchers start with a very small dose and incrementally increase until signs of toxicity appear. Efficacy and responsiveness data are collected, but it’s not yet the main goal.

Phase 2: Once the dose is established, researchers begin looking at efficacy and responsiveness. An indicator in many clinical trials is how much tumours shrink.

Phase 3: The novel drug or treatment is compared to the previous standard of care. If the new treatment shows improvements in survival, it usually becomes the new standard of care.

Phase 4: Phase four trials happen once the agent is established as a new standard of care. They operate like population-based studies in function, looking into the benefits of the treatment in broader use.

Originally published in Leap Magazine.